Hutchmed signs exclusive development and license deal with GSK
Hutchmed (China) said it entered an exclusive development and license agreement with GSK for a cancer drug, including a $110 million upfront payment and milestone payments for development, regulatory and commercial goals.
By Amanda LeeBiopharmaceutical firm Hutchmed (China) said it has entered into an exclusive development and license agreement with U.K. drugmaker GSK for a cancer drug.The deal includes a $110 million upfront payment, and potential development, regulatory and commercial milestone payments for up to…